

# **2022 Oman Infectious Disease Testing Market-Growth Opportunities, Supplier Shares by Test, Segmentation Forecasts for 100 Respiratory, STD, Enteric, and other Virology, Bacteriology, Parasitology and Mycology Assays-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks**

<https://marketpublishers.com/r/2F068AB9B41EEN.html>

Date: November 2022

Pages: 0

Price: US\$ 2,500.00 (Single User License)

ID: 2F068AB9B41EEN

## **Abstracts**

This unique report from LeadingMarketResearch.com provides information not available from any other source, including test volume and sales forecasts for 100 individual tests, and competitor strategies. The report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the infectious disease testing market during the next five years.

The report is available by section, and can be customized to specific information needs and budget. The report reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

### **Rationale**

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.

The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

### Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

### Current and Emerging Products

In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.

Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.

### Technology Review

Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.

Companies developing or marketing infectious disease diagnostic products by

individual test.

## Opportunities and Strategic Recommendations

Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.

Design criteria for decentralized testing products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

## Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

## Contents

### I. INTRODUCTION

### II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

#### A. Major Infectious Disease Tests

1. AIDS
2. Adenovirus
3. Aeromonads
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Chagas Disease
13. Chancroid
14. Chlamydia
15. Clostridium Difficile
16. Coronaviruses
17. Cocksackieviruses
18. Creutzfeldt-Jakob's Disease
19. Cryptosporidium Parvum
20. Cyclospora Cayetanensis
21. Cytomegalovirus
22. Ebola Virus
23. E. Coli
24. Echovirus
25. Encephalitis
26. Enteroviruses
27. Epstein-Barr Virus
28. Giardia Lamblia
29. Gonorrhea
30. Granuloma Inguinale
31. Hantavirus
32. Helicobacter Pylori

33. Hepatitis
34. Herpes Simplex Virus
35. Human Herpes Virus-6 (HHV-6)
36. Influenza Viruses
37. Legionella
39. Lymphogranuloma Venereum (LGV)
40. Malaria
41. Measles (Rubeola)
42. Meningitis
43. Microsporidium
44. Mononucleosis
45. Mumps
46. Mycoplasma
47. Papillomaviruses
48. Parvovirus B19
49. Pneumonia
50. Polyomaviruses
51. Pseudomonas Aeruginosa
52. Rabies
53. Respiratory Syncytial Virus (RSV)
54. Rhinoviruses
55. Rotavirus (REOVIRUS)
56. Rubella (MEASLES)
57. Salmonellosis
58. Septicemia
59. Shigellosis
60. Staphylococcus Aureus
61. Streptococci
62. Syphilis
63. Toxoplasmosis
64. Trichomonas Vaginalis
65. Tuberculosis
66. Vibrio
67. West Nile Virus
68. Yersinia

B. Instrumentation Review: Operating Characteristics, Features and Selling Prices of Leading Automated and Semi-automated Analyzers

C. Emerging Diagnostic Technologies

**III. MARKET SIZE, GROWTH AND SALES FORECASTS BY TEST****IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES****V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS****VI. ALTERNATIVE MARKET PENETRATION STRATEGIES****VII. DISTRIBUTION STRATEGIES FOR DECENTRALIZED TESTING MARKETS****VIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS****IX. COMPETITIVE ASSESSMENTS**

Abbott

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biokit

bioMerieux

Bio-Rad

Decode Genetics

Eiken Chemical

Elitech Group

Enzo Biochem

Exact Sciences

Fujifilm Wako

Fujirebio

Grifols

Hologic

Illumina

Leica Biosystems

Li-Cor Biosciences

Myriad Genetics

OrthoQuidel

PerkinElmer

Proteome Sciences

Qiagen  
Quest Diagnostics  
Roche  
Scienion  
Sequenom/LabCorp  
Shimadzu  
Siemens Healthineers  
Sierra Molecular  
Takara Bio  
Tecan Group  
Thermo Fisher

## I would like to order

Product name: 2022 Oman Infectious Disease Testing Market-Growth Opportunities, Supplier Shares by Test, Segmentation Forecasts for 100 Respiratory, STD, Enteric, and other Virology, Bacteriology, Parasitology and Mycology Assays-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

Product link: <https://marketpublishers.com/r/2F068AB9B41EEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2F068AB9B41EEN.html>